No Data
No Data
ST Jingfeng (000908.SZ): Stocks trade with serious abnormal fluctuations, without disclosing any significant information.
On July 17th, Gelunhui reported that the stock (*ST Jingfeng, stock code: 000908) of Jingfeng has deviated from the closing price for the past three consecutive trading days between July 15th and July 17th of 2024, with a cumulative increase of 17.01%. According to the relevant provisions of the Shenzhen Stock Exchange Trading Rules, it belongs to abnormal fluctuations in stock trading; at the same time, the company's stock has appeared abnormal fluctuations in the same direction in 4 out of the last ten consecutive trading days, which constitutes serious abnormal fluctuations in stock trading. The board of directors confirmed that the company currently has no basis for trading.
Hunan Jingfeng Pharmaceutical: 2024 Interim Performance Forecast
*Special treat Jingfeng (000908.SZ): Expected half-year loss of 15 to 25 million yuan.
On July 9, Gelon Hui reports that ST Jingfeng (000908.SZ) predicts a loss of 15-25 million yuan in the first half of the year, with non-net losses of 18-27 million yuan and operating income of 180-220 million yuan. During the reporting period, due to factors such as insufficient outsourcing production volume of major subsidiary Shanghai Jingfeng Pharmaceutical Co., Ltd., the net profit of the company was negative. During the reporting period, the exclusion of major subsidiary Dalian Deze Pharmaceutical Co., Ltd. from the company's consolidated financial statements had an impact on various key financial indicators.
July 8 A-share lightning rod | Naxin Micro: multiple shareholders plan to reduce their holdings by no more than 6% of shares;* Special Treat Jingfeng: the stock is at risk of being delisted.
Several shareholders of NAXIN Micro plan to reduce their shareholding by no more than 6%. Kaishan Group has about 0.136 billion restricted stocks to be lifted on July 8, accounting for 13.65% of the total shares. Special Treat Jingfeng stock faces the risk of being delisted. Jiangsu Zhongli Group received an administrative penalty decision from the China Securities Regulatory Commission.
Risk Warning for ST Jingfeng (000908.SZ): There is a risk of the company's stocks being delisted.
On July 5th, Gelunhui announced the second risk warning about the possible delisting of * ST Jingfeng (000908.SZ). On July 5, 2024, the closing price of Hunan Jingfeng Pharmaceutical Co., Ltd.'s stock was below 1 yuan for ten consecutive trading days. According to Article 9.2.1 (4) of the Shenzhen Stock Exchange Listing Rules, if the company's stock has a closing price below 1 yuan for twenty consecutive trading days, there is a risk of delisting. According to Article 9.2.4 of the Shenzhen Stock Exchange Listing Rules, the listed company must
ST Jingfeng (000908.SZ): The controlling shareholder plans to increase the shareholding of the company by 2-4 million yuan.
On June 24th, Gelunhui reported that *ST Jingfeng (000908.SZ) announced that the company's controlling shareholder plans to increase its shareholding in the company between June 25th, 2024 and September 24th, 2024 through the Shenzhen Stock Exchange's centralized bidding trading system using its own funds, with a total increase of no less than 2 million yuan (including the principal) and no more than 4 million yuan (including the principal), based on the recognition of the company's long-term investment value and future development prospects.
No Data